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Ex vivo modelling of drug efficacy in a rare
metastatic urachal carcinoma
Rami Mäkelä1, Antti Arjonen1,2, Ville Härmä1,3, Nina Rintanen4, Lauri Paasonen5, Tobias Paprotka6, Kerstin Rönsch6,
Teijo Kuopio4, Juha Kononen4,7 and Juha K. Rantala1,3*
Abstract
Background: Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital
tumor cells. The purpose of these methods is to enable functional testing of patient specific efficacy of anti-cancer
therapeutics and personalized treatment strategies. Such approaches could prove powerful especially in context of
rare cancers for which demonstration of novel therapies is difficult due to the low numbers of patients. Here, we
report comparison of different ex vivo drug screening methods in a metastatic urachal adenocarcinoma, a rare and
aggressive non-urothelial bladder malignancy that arises from the remnant embryologic urachus in adults.
Methods: To compare the feasibility and results obtained with alternative ex vivo drug screening techniques, we
used three different approaches; enzymatic cell viability assay of 2D cell cultures and image-based cytometry of 2D
and 3D cell cultures in parallel. Vital tumor cells isolated from a biopsy obtained in context of a surgical debulking
procedure were used for screening of 1160 drugs with the aim to evaluate patterns of efficacy in the urachal
cancer cells.
Results: Dose response data from the enzymatic cell viability assay and the image-based assay of 2D cell cultures
showed the best consistency. With 3D cell culture conditions, the proliferation rate of the tumor cells was slower
and potency of several drugs was reduced even following growth rate normalization of the responses. MEK, mTOR,
and MET inhibitors were identified as the most cytotoxic targeted drugs. Secondary validation analyses confirmed
the efficacy of these drugs also with the new human urachal adenocarcinoma cell line (MISB18) established from
the patient’s tumor.
Conclusions: All the tested ex vivo drug screening methods captured the patient’s tumor cells’ sensitivity to drugs
that could be associated with the oncogenic KRASG12V mutation found in the patient’s tumor cells. Specific drug
classes however resulted in differential dose response profiles dependent on the used cell culture method
indicating that the choice of assay could bias results from ex vivo drug screening assays for selected drug classes.
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Background
The development of high-throughput screening tech-
nologies and cell culture methods has made it feasible to
perform large-scale in vitro drug screens also using pa-
tient derived primary tumor cell cultures [1–3]. These
techniques are collectively called as ex vivo drug screen-
ing methods. The utility of ex vivo drug screening has
emerged as a novel approach to complement patho-
logical cancer diagnostic procedures to track patient spe-
cific drug sensitivity to hundreds of cancer therapeutics
in a single experiment [3]. The results can be used to
confirm drug sensitivity patterns predicted from molecu-
lar genetics [2] or to inform treatment decision and per-
sonalized care of individual cancer patients when
standard treatment options have been exhausted [3]. In
context of rare cancers, the low number of patients
limits the clinical evaluation and validation of novel
treatment strategies using conventional trial mecha-
nisms. Thus, demonstration of the efficacy of novel ther-
apeutics in rare cancer types through empirical evidence
from ex vivo tests or similar alternative models may be
the only option to motivate clinical development of
these treatments [3–5]. One such rare cancer, for which
ex vivo evidence could be used as motivation for devel-
opment of novel treatment strategies, is urachal cancer,
an aggressive non-urothelial bladder malignancy ac-
counting for less than 1% of all bladder cancers [6]. Ura-
chal adenocarcinoma (UrAC) arises in adults from the
vestigial musculofibrous remnant band that connects the
allantois and the bladder during embryonic develop-
ment. A large proportion of patients with UrAC initially
present with an advanced disease [7] and patients with
metastatic urachal cancer have a poor prognosis [8–11].
Given the rarity of urachal cancers, prospective trials to
guide the treatment of patients with advanced disease
are lacking, there are no standard chemotherapeutic reg-
imens, and surgery remains the mainstay of therapy
shown to improve the overall survival outcome of UrAC
[12]. To date, no randomized trials of urachal carcin-
omas have been reported and the most comprehensive
reviews to date have concluded 420 [10] and 456 [11]
patients reported regionally and 1010 patients reported
globally [13]. As a result, limited information exists re-
garding the effective management of these cancers be-
yond the use of chemotherapy including 5-fluorouracil
based, 5-fluorouracil and cisplatin [14–17] or hyperther-
mic intraperitoneal chemotherapy [18–20]. Especially,
knowledge concerning the efficacy of new genome aber-
ration targeted chemotherapeutic agents is limited to a
handful of case reports from individual institutions [14,
21–25]. Moreover, comprehensive tumor genomic pro-
filing of UrAC samples has not been described and the
only common genetic features described in the limited
number of reported cases have included aberration of
APC, BRAF, EGFR, KRAS, PIK3CA, TP53 and microsat-
ellite instability [21–26]. To improve our understanding
of the disease pathogenesis and therapy sensitivity of
UrAC, we performed a large-scale ex vivo drug screen-
ing of 1160 drugs with vital tumor cells derived from a
patient with a metastatic urachal adenocarcinoma. In
this study, we also compared the reproducibility of re-
sults derived with three different high-throughput drug
screening approaches to assess assay dependency of the
ex vivo measured dose responses of the patient derived
tumor cell cultures. Last we describe establishment of a
new human urachal adenocarcinoma cell line (MISB18)
which is the first described UrAC cell line with a known
genetic background.
Methods
Patient derived primary tumor cell culture
The patient was identified to the study by an oncologist
at Jyväskylä Medical Central, Finland. A subcutaneous
metastasis tissue sample was collected for the study dur-
ing palliative surgery. In conjunction with the surgical
procedure, part of the dissected tumor tissue was placed
in sterile RMPI-1640 medium (Gibco) for transport to
the consulting pathologist for preparation and further
delivery to the research laboratory (Fig. 1a). Rest of the
tissue was fixed in 4% buffered formaldehyde, paraffin-
embedded, cut at 4 μm, and subjected to routine staining
procedures including hematoxylin and eosin stain (H&E)
and pathological evaluation (Fig. 1b). The live tissue was
dissociated into a single cell suspension as described be-
fore [3]. Following the enzymatic dissociation, the result-
ing cell suspension was counted using a Cellometer
Mini cell counter (Nexcelom). In total 6.5 × 10^6 cells
with an average size of > 13 μm was derived from ~2cm3
of the tumor tissue. The suspension was diluted to
RPMI-1640 medium (Gibco) containing 5% FBS to
achieve a suspension with 1000 cells per 45 μL of
medium. 5 × 10^6 cells were used for the initial ex vivo
drug screening and the rest were placed to cell culture
in standard cell culture conditions (37 °C, 5% CO2). Fol-
lowing 4 days in culture, the cells presented a semi-
adherent phenotype with cells growing both as loose ag-
gregates and adhered to the plastic cell culture surface
(Fig. 1b). The use and investigation of the patient de-
rived cells was approved by the local Ethics Committee
of the Central Finland Health Care District (KSSHP 3 U/
2015). All the experiments were undertaken with the un-
derstanding and written informed consent of the patient.
The study methodologies conformed to the standards
set by the Declaration of Helsinki.
Ex vivo drug screening
The therapeutic compound collection used in the
ex vivo study consisted of 1140 FDA approved drugs,
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purchased as single a collection of FDA approved drugs
from a commercial chemical vendor (Cat.no. L1300,
Selleck biochemicals, Houston, TX, USA) readily dis-
solved in dimethyl sulfoxide (DMSO). The library was
supplement with 20 investigational and preclinical com-
pounds covering key cancer associated signaling pathway
targets including AKT, ATR, BET (bromodomain),
EGFR, FGFR, MDM2, MEK, PIM, PI3K, pan-RAF and
WEE1. Since platinum-based drugs (cisplatin, carbopla-
tin and oxaliplatin) are inactivated by DMSO, these were
replaced in the compound library with stock solutions
diluted in physiological saline. The ex vivo drug screen-
ing experiments were performed in 384-well microplate
format as described before [3]. Briefly, each compound
was tested in the initial high content image-based
screening with three different concentrations in 2-fold
dilutions starting from 5 μM as the highest concentra-
tion. In the secondary screening experiments, the
compounds were tested in five 2-fold concentrations
starting from 5 μM as the highest concentration. For
the screening experiments performed with 2D cell
cultures, the compounds were pre-printed on tissue
culture treated 384-well plates (Corning, Thermo-
Fisher Scientific) diluted in 5 μl of RPMI-1640
medium without supplements with a liquid handling
device (Eppendorf EpMotion-96, Eppendorf GmbH.).
For the screening experiment performed with 3D cell
cultures, the compounds were aliquoted on top of the
3D cell cultures in 10× concentration. Cell suspension
of freshly isolated urachal carcinoma cells (45 μl per
well; 1000 cells per well) was then transferred to each
well using Multi-Drop Micro peristaltic dispenser
(ThermoScientific). The 384-well plates were then in-
cubated for 72 h at 37 °C and 5% CO2.
Enzymatic cell viability assay
To assess drug induced growth inhibition with an en-
zymatic cell viability assay following a 72-h incubation of
the cells with drugs, cell viability was measured using
CellTiter-Glo reagent (Promega) according to the manu-
facturer’s instructions with Labrox luminescence plate
reader (Labrox). Briefly, 20 μL of the reagent was added
Fig. 1 Overview of the study design and the patient sample. a A surgically resected tumor sample from a metastatic nodule on the patient’s neck was
received for the study. Tumor cells were isolated on day of surgery and used immediately for ex vivo drug screening of 1160 drugs. 2D and 3D cell
culture assay approaches were used in parallel to evaluate reproducibility of the results. Image-based assays and the enzymatic cell viability assay
results were normalized using growth rate normalization. b Left: Haematoxylin & eosin staining of the metastatic urachal adenocarcinoma tissue
showing poorly differentiated neoplastic cells, bar 250 μm. Right; transmitted light microscopy image of the tumor derived cell culture at day 4 after
dissociation of the cells, bar 100 μm
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per 384-well and incubated for 30 min at room
temperature in gentle shaking. Cell viability lumines-
cence data was normalized to median luminescence sig-
nal from 0.05% DMSO only wells (negative controls), 2
mM hydroxyurea containing wells (proliferation growth
controls) and 5 μM staurosporin containing wells (posi-
tive controls). Dose response was presented as growth
rate (GR) normalized % of signal in comparison to nega-
tive and positive control samples (see Statistical
analysis).
Image-based cell viability assays
Microscopic image-based drug screening with 2D cell
cultures was performed using an Olympus scan^R inte-
grated high content imager and image analysis suite
(Olympus) equipped with a Hamamatsu ORCA-R2 CCD
digital camera (Hamamatsu Photonics K.K). Each well
was imaged individually with a 10× objective using spe-
cific filter sets for DAPI (Semrock). The scan^R image
analysis software suite was used for quantitative analysis
of image features. Analysis capabilities included cell seg-
mentation based on nuclear DNA staining and cell
counting. The effects of each drug on cell counts as indi-
cator of cell growth inhibition or cytotoxicity were
assessed by comparing cell counts with comparable cell
counts measured in DMSO only wells (negative con-
trols) and 2mM hydroxyurea containing wells (prolifera-
tion controls). The DNA counterstaining of the cells was
performed according to the following protocol. First the
culture medium was aspirated carefully from each well
and the cells were fixed with 2% paraformaldehyde
(Sigma-Aldrich) in PBS for 15 min at room temperature.
Cells were then washed once for 5 min with PBS. Cells
were permeabilized with 0.3% Triton-X100 in 20 μL of
PBS for 15 min at room temperature, followed with a
PBS wash. DAPI (4′,6-diamidino-2-phenylindole, Invi-
trogen) DNA counterstaining was performed for 1 h at
room temperature, followed by washing with PBS (Sup-
plementary Figure 1).
3D cell culture assays with imaging cytometry
The 3D cell culture assays were performed using Grow-
Dex® hydrogel (UPM, Helsinki, Finland) as the matrix
supporting 3-dimensional cell growth. To minimize ad-
herent cell growth in the bottom surface of the wells,
the microwells were first coated with 1.2% pHEMA (poly
(2-hydroxyethyl methacrylate; Polysciences). For the ex-
periment the 1.5% hydrogel stock was mixed with
complete cell culture medium (RPMI-1640 + 5% FBS) to
achieve a 0.6% w/v hydrogel solution. 30 μL of cell sus-
pension containing 2000 cells was mixed with 30 μL of
the diluted hydrogel to achieve a 0.3% w/v hydrogel so-
lution containing ~ 30 cells/μL. Required amount of
hydrogel-cell solution was prepared by pipetting the
hydrogel using a wide-mouth 10 mL pipetting tip into a
50mL tube and gentle mixing with a vortex shaker. The
hydrogel-cell solution was dispensed to 384-plate wells
using a Multidrop plate dispenser (ThermoFisher Scien-
tific). The total volume of sample added into a single
384-well was 60uL/well (2000 cells). Following dispens-
ing, plates were centrifuged for 1 min at 100 g and left
on incubation at + 37 °C, 5% CO2 for 7 days prior to
addition of the drugs. At day 4, 20 μL of medium was
carefully aspirated from the wells using a multichannel
pipet and 20 μL of fresh complete cell culture medium
was added to each well. On day 7, the same was repeated
followed by addition of 6 μL of the 10× drug stocks per
well and additional 72-h incubation. For analysis of cell
growth, the cells were stained using Hoechst 33342 cell
permeant live cell DNA dye (Invitrogen). 8 μL of 10×
stock dilution was added per well and incubated for 45
min. Following Hoechst staining, the plates were
centrifuged for 2 min at 200 g to settle the cell spher-
oids/aggregates to the bottom plane of the wells (Supple-
mentary Figure 1). Imaging and image analysis were
then performed using an Olympus scan^R high content
imager and image analysis suite as described above for
the 2D assays.
Mutation analysis
Targeted genomic profiling of an oncopanel with 850
cancer associated genes was performed from the ex vivo
tumor cell culture following 1 month in culture. Gen-
omic DNA was extracted from 1 × 10^6 cells using
NucleoSpin Tissue (Macherey-Nagel GmbH) DNA puri-
fication kit according to the manufacturer’s protocol.
Hybridization-based target capture was performed with
Agilent SureSelect (Agilent) technology and sequencing
libraries were sequenced using paired end 100 bp read
format on an Illumina HiSeq2500 instrument per the
manufacturer’s instructions (Illumina). Single nucleotide
variants (SNVs), insertions and deletions (In/Del) were
detected and filtered based on mutation allele frequency
(> 1%). Detected variants were screened for known clin-
ical significance in ClinVar (released 02. Oct 2017) data-
base [27]. Result are available online at Mendeley data;
DOI: https://doi.org/10.17632/kc7wmn3rcs.2.
Statistical analysis
Statistical analysis was performed with the Microsoft Excel,
Cluster 3.0 and GraphPad Prism 7 statistical software. The
ex vivo drug screening data was analyzed using the normal-
ized growth rate inhibition (GR) approach which yields per-
division metrics for drug potency and efficacy. The normal-
ized growth rate inhibition (GR) method corrects for
variation in division rates by estimating the magnitude of
drug response on a per cell-division basis. The GR values
were used for comparison of drug potency between the
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different screening methods to correct for differential prolif-
eration rate of the cells in 2D and 3D culture conditions. GR
values were calculated as previously described [2, 3]. Com-
bination indices (CI) were calculated from replicate, fixed-
ratio, dose escalation experiments using the Chou and Tala-
lay method [28]. CI values were reported at 50% inhibitory
values (CI50). IC50 values were calculated with GraphPad
Prism 7 software using a nonlinear curve fit equation. Due to
the limited number of primary cells available for technical
replicate screening experiments, different drug test doses
were considered as biological replicates, and the correspond-
ing p-values were calculated across the dilution series with
Welch’s t-test according to assumptions on data normality.
Results
Ex vivo drug screening of urachal cancer cells
The patient, a 36-year-old male was diagnosed with a 9
cm cystic-solid tumor in front of bladder. The tumor
cells infiltrating bladder epithelium demarcated sharply
from the urothelium. Initial treatment included cystec-
tomy and wide pelvic lymphadenectomy. Pathological
evaluation of the surgical preparation confirmed the
diagnosis of urachal mucinous cystadenoma and poorly
differentiated urachal carcinoma. Carcinoma fraction of
the tumor contained various different regions with
mixed histological features, including partial differenti-
ation to urothelial carcinoma, intestinal carcinoma and
squamous cell carcinoma. Cancer showed high prolifera-
tion rate, mitotic figure count was 40/10 HPF. Up to
30% of the tumor contained necrotic tissue. Adjuvant
treatment of the patient consisted of six cycles of cis-
platin – 5-FU regimen. Immediately after adjuvant
chemotherapy patient presented with subcutaneous
metastatic lesion located behind left ear. Patient received
radiotherapy with a palliative intent (30 Gy, 10 × 3 Gy).
Disease progressed shortly after completing radiotherapy
course and second-line systemic chemotherapy was initi-
ated with docetaxel – gemcitabine. Disease progressed
again and new lesions appeared in multiple locations
(neck, axilla, sternum, adrenal gland, peritoneal region,
sacrum). At this stage, palliative debulking surgery was
performed on a painful subcutaneous lesion on the neck
[29]. A section of tumor tissue was collected for the pur-
pose of ex vivo therapy efficacy screening and a section
was prepared for histopathology confirming metastatic
urachal adenocarcinoma showing poorly differentiated
neoplastic cells (Fig. 1b). Using standard techniques to
establish cell cultures from human tissues [30], a pri-
mary cell culture was prepared for the drug screening
experiment on the day of the surgery. Cytotoxicity of
1160 drug compounds representing all different FDA ap-
proved drug classes, with a fixed dose range of 1.25 μM
to 5 μM was performed with the primary tumor cell cul-
ture (Mendeley data: DOI: https://doi.org/10.17632/
kc7wmn3rcs.2). With comparison of the negative control
samples and hydroxyurea treated proliferation control
samples, the estimated cell doubling rate of the primary
culture was calculated to be 240 h corresponding to ~
0.3 cell division over the course of the 72-h assay. To
identify the most potent growth inhibitory drugs, effects
of the drugs were averaged across all the test concentra-
tions to derive a stringent ranking criterion where the
growth inhibitory impact of the drug had to be stronger
than the cell growth stalling effect of hydroxyurea (GR <
0) across all test doses (Fig. 2a). From this, 49 drugs
resulting in a strong cytotoxic effect were nominated
(Fig. 2b). These included 19 drugs used or developed for
anticancer purposes (antimetabolites, microtubule poi-
sons, nucleoside analogs, topoisomerase inhibitors, tar-
geted therapeutics including WEE1, CDK4/6, mTOR,
HDAC and a novel BET inhibitor ODM-207), as well as
30 drugs with other indications including statins and
antibiotic compounds (Fig. 2b). The most potent growth
inhibitory compound from the panel of 1160 drugs was
Monensin, a monocarboxylic acid ionophore veterinary
drug produced by Streptomyces cinnamonensis with anti-
biotic and anticancer activity [31, 32].
Validation using different ex vivo screening techniques
To validate findings from the primary drug screen and
to evaluate dependency of the drug efficacy profiles on
the used assay technique, a repeated analysis of 90 se-
lected drugs with an expanded dose range was per-
formed using three different high-throughput screening
approaches; an enzymatic 2D cell viability assay, an
imaging-based 2D cell viability assay and an image-based
cell viability assay of cells cultured in 3D cell culture
conditions (Fig. 3a). All drugs were tested with five 2-
fold concentrations and dose responses were normalized
using GR metrics to correct for the differential measured
cell growth rate of ~ 0.6, ~ 0.5 and ~ 0.3 cell doublings
per 72 h in the image-based 2D, enzymatic 2D and
image-based 3D assay respectively (Fig. 3b). Unsuper-
vised hierarchical clustering of the dose responses across
all three different assay methods was performed to iden-
tify patterns of response among the drug classes and to
visualize variation in the response dependent on the
used assay method (Fig. 3a). The overall most cytotoxic
drugs independent of the assay method, based on growth
rate normalized dose responses, were afatinib (2nd gen-
eration EGFRi, IC50 3,83 μM), AZD2014 (mTOR1/2i,
IC50 0,36 μM), bortezomib (proteasome inhibitor, IC50
1,24 μM), cladribine (purine analogue, IC50 3,57 μM),
ODM-207 (bromodomain inhibitor, IC50 1,01 μM) and
paclitaxel (taxane, IC50 3,38 μM) (Fig. 3c, d). The me-
dian IC50 of mTOR inhibitor AZD2014 (vistusertib)
when measured across the three different assay methods
was lower by ~ 10× to ~ 20× in comparison to 5-FU,
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docetaxel, ciplatin or gemcitabine, agents that had been
used to treat the patient. Interestingly, all included topo-
isomerase inhibitors; camptothecin, doxorubicin, irinote-
can and topotecan resulted in more potent cytotoxic
effects in the 3D cell culture assay (Fig. 3e) [33]. Overall,
the drug response data measured with the enzymatic 2D
assay and the image-based 2D assay had the highest de-
gree of concordance across the full dose range (Pearson
correlation, average across all doses, r = 0.45). In general,
the cytotoxic effects of majority of drugs were less po-
tent in the 3D assay with the exception of topoisomerase
inhibitors, docetaxel and vincristine.
Evaluation of targeted drug combinations
Results of the ex vivo screening indicated an apparent
MAPK/PI3K signaling pathway switch in the tumor cells
based on the high sensitivity of the cells to mTOR inhib-
ition, MEK inhibition and partial response also to antifo-
late abitrexate, BRAF and EGFR inhibition. Other
targeted therapeutics displaying cytotoxic effects were
the ALK/ROS1/cMET inhibitor crizotinib, experimental
bromodomain inhibitor ODM-207 and several VEGFR
angiogenesis inhibitors (Fig. 3a). Efficacy of these com-
pounds varied only little between the different ex vivo
assay techniques indicating no dependency on the mode
of cell growth (2D vs. 3D) (Fig. 3a). The RAS/RAF/
MEK/ERK and PI3K/AKT/mTOR signaling pathways all
belong to mitogen-activated protein kinase (MAPK) sig-
naling pathways. Mutations and/or activation by other
mechanism of any one of the upstream genes (such as
KRAS, BRAF, EGFR or MET) may result in abnormal
activation of the signaling pathway converting into sensi-
tivity towards inhibition of the MAPK signaling pathway
[34]. Comparison of the sensitivity of patient derived
tumor cells with the sensitivity of primary cultures previ-
ously derived from three urothelial bladder carcinomas
and one small-cell neuroendocrine bladder carcinoma
with no known MAPK pathway activating mutations [1]
confirmed the selective sensitivity of the urachal cancer
cells to the mTORC1/2 inhibitor AZD2014, MEK inhibi-
tor trametinib and EFGR inhibitor afatinib (Supplemen-
tary Figure 2). To assess the genetic background of the
patient’s tumor cells a targeted oncopanel DNA sequen-
cing was performed from tumor cells kept in continuous
Fig. 2 Large-scale ex vivo drug screening in patient derived urachal carcinoma cells. a Scatter plots comparing the GR value correlation of all the
drugs in the different test concentrations. A compound library of 1160 drugs was used to assess cytotoxicity on urachal cancer cells following 72-
h exposure. Analysis was performed using an imaging cytometry assay and GR scoring. Drugs reducing cell viability more that the proliferation
stalling control hydroxyurea (GR < 0) in all concentrations were considered significant. b 49 most effective cytotoxic compounds reducing cell
viability (GR < 0) across all test concentrations. GR values of the 3 drug doses stacked and compounds ordered by the averaged cytotoxicity. Drug
target/class of each drug is indicated with the different colors
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culture for 1 month following the drug screening experi-
ments. Two known pathogenic mutations associated also
with urachal cancers; FGFR4 and KRAS [23] and seven
known mutations associated with a drug response were
identified in the patient’s tumor cells (Table 1.).
As suggested by the responsiveness of the patient’s
cells to MEK inhibitor trametinib [34], the tumor cells
were found to harbor a somatic activating KRASG12V
mutation reflecting results from earlier studies reporting
KRAS mutations being more common in UrAC than in
urothelial bladder cancers [12]. For an in-depth view on
potential drug combinations that could be synergistic
with MEK inhibition in the treatment of KRAS mutated
UrAC, we explored the effects of combining MEK in-
hibitor trametinib with the mTORC1/2 inhibitor
AZD2014, ALK/cMET inhibitor crizotinib and BRAF
Fig. 3 Ex vivo validation screening using different assay techniques. a Heatmap display of vertical unsupervised clustering of the dose response
data of the drugs from independent ex vivo screens using a 2D enzymatic cell viability assay, an image-based 2D cell viability assay and an
image-based 3D cell viability assay. Each drug was tested in five concentrations. GR values < 0 shown in blue. b Comparison of the assay controls
used to calculate growth rates of the patient derived cells in the 2D and 3D culture conditions and measured with the different assay techniques.
c Venn diagram showing the overlap of the top 30 most cytotoxic drugs from the different assay techniques. d Curve fitted dose response curves
of the most potent cytotoxic drugs across all three different replicate screens. e Topoisomerase inhibitors had systematically a more potent
cytotoxic effect in the 3D cell culture model assay
Table 1 Clinical significance SNVs identified in the patient’s tumor cells
Gene AA Change Codon Change Mutation freq. ClinVar ID ClinVar significance
ABCB1 p.S829A, pS893A c.2677 T > G, c.2485 T > G 31,8% rs166622 drug response
DPYD p.M166V c.495A > G 47,1% rs100116 drug response
FGFR4 p.G23R, p.G388R c.67G > A, p.1162G > A 100,0% rs16326 pathogenic
KRAS p.G12V c.35G > T 71,6% rs12583 pathogenic
SLCO1B1 p.V174A c.521 T > C 99,8% rs37346 drug response
TAS2R38 p.I296V c.886A > G 99,9% rs2906 drug response
TAS2R38 p.A49P c.145G > C 100,0% rs2904 drug response
TP53 p.P33R, p.P72R c.98C > G, c.215C > G 99,7% rs12351 drug response
XPC p.Q939K c.2815C > A 100,0% rs190215 drug response
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inhibitor vemurafenib having cytotoxic effects both on
the 2D and 3D assays (Supplementary Figure 1). The
MISB18 cell line established from the patient’s tumors
were tested with a matrix of the inhibitor combinations
in six doses. Trametinib was administered in six 3-fold
dilutions starting from 2 μM and the other drugs in six
3-fold dilutions starting from 5 μM. Combination treat-
ments with MEK and mTOR inhibition and MEK and
ALK/cMET inhibition revealed additive effects of cyto-
toxicity (CI50 = 0.16, CI50 = 0.45 respectively), resulting
in significant net reduction in cell numbers following 72
h of treatment (Fig. 4a). Cytotoxic IC50 of trametinib
and AZD2014 as a combination at a fixed molar ratio of
1 to 2.5 was < 10 nM, compared to IC50 values of 80 nM
and 240 nM of the drugs as single agents, respectively
(Fig. 4a & b). This finding is consistent with the role of
kinome reprogramming and the alternate RTK signaling
pathways feeding in the development of acute resistance
to MEK inhibition cancer cells [35]. Also, the synergistic
effect of inhibition of ALK/ROS1/cMET upstream of the
MAPK pathway in combination with MEK inhibition fits
concept as ROS1 inhibition has been previously shown
to potentiate the anticancer effect of trametinib [35].
Discussion
The last decade of cancer research marks the era for
evolution of the concept of personalized cancer care
through the revolution of genetics and targeted
therapies. In clinical oncology settings, the application of
genomic medicine has been pioneered towards clinical
trials where systemic cancer treatment is being targeted
to individual patients based on molecular
characterization of the patient’s tumor [36]. This is par-
ticularly promising in context of clinical care of rare
cancers, for which large clinical studies are not possible
due to low number of cases. Treatment of rare cancers
is often based on empirical approaches with standard
chemotherapies. With advanced disease these treatments
often fail, and no additional therapeutic options are
available due to lack of clinical evidence on targeted
treatments. In the future, combination of diagnostic
therapy efficacy screening with genomic information [1–
3, 37–40] could provide a robust diagnostic approach
for personalized cancer medicine including immuno-
oncology therapies [41] and thereby shift the clinical
practice paradigm also in rare cancers. Currently the
ex vivo screening techniques are under intense develop-
ment and multiple different approaches has been de-
scribed by different research groups [1–3, 37–41]. A
common topic of debate regarding the ex vivo drug
screening methods is the in vivo representativeness of
the used models. 3D cell culture models have been pro-
moted to increase the success rate of primary tumor cell
cultures and resemble the primary tumors better than
traditional two-dimensional (2D) cell culture models.
This is in part due to potential transformation and loss
Fig. 4 Evaluation of potent drug combination strategies in urachal cancer cells. a Dose–response matrices of percent of cell viability resulting
from exposure to the indicated drug combinations. Drugs were tested in 6 concentration in a matrix covering all possible combination of the
dilutions in triplicate. Cells were exposed to the drugs for 72 h in 2D cell culture. b Curve fitted dose response curves and a table with the IC50
estimates of the single agents and the CI50 combination index values for the drugs at a fixed molar ratio of 1 to 2.5
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of heterogeneity of cancer cell cultures under conven-
tional 2D in vitro propagation. Here, both 2D and 3D
cell culture conditions were tested in parallel to compare
the reproducibility of the methods. While the image-
based and enzymatic 2D cell culture assays had the best
overall correlation of the dose response results, all three
techniques yielded dose and target dependent cytotoxic
profiles for drugs which could be linked directly to gen-
omic features of the patient’s cancer. Many drugs had
also a significantly stronger cytotoxic effect in both the
2D and 3D assay than the standard chemotherapeutics
that are being used for treatment of UrAC including the
current patient. This shows that ex vivo therapy efficacy
screening could be used as a rapid technique to comple-
ment pathological and clinical diagnostics to inform on
treatment decisions [3]. Indeed, results from the first re-
ported clinical trial utilizing ex vivo drug screening indi-
cated a 88% overall response rate (ORR) for patients
treated on basis of the approach [37]. This suggest that
ex vivo screening has the potential for high accuracy in
predicting responsive patients.
Conclusion
To evaluate feasibility and reproducibility of different
ex vivo drug screening approaches to model thera-
peutic options for metastatic urachal adenocarcinoma,
we performed a large-scale ex vivo drug screening
using tumor cells freshly isolated from an UrAC
tumor biopsy. The primary drug screening of 1160
drugs was initiated on the day of surgery and the
screening results were available 4 days after sampling
of the tissue. Findings from the initial screening were
confirmed by alternative ex vivo screening techniques
based on 2D and 3D cell culture models and two dif-
ferent assay approaches. All different assay techniques
suggested sensitivity of the patient’s tumor cells to-
wards inhibition of MAPK signaling pathway targets
MEK and mTOR. Targeted NGS profiling of the pa-
tient’s cells confirmed an activating KRASG12V muta-
tion giving a rationale for the increased sensitivity of
the tumor cells to MAPK signaling pathway. While
our study is limited by the analysis of only a single
UrAC patient sample, the significance of the results is
the demonstration that rapid ex vivo screening with-
out prior in vitro propagation of the patient derived
tumor cells, both with 2D and 3D cell culture sys-
tems, identified drug sensitivities that reflected the
genomic profile of the patient’s tumor. Moreover, we
describe the first UrAC cell line (MISB18) with a
known tumor genomic profile, which together with
future analyses of additional ex vivo UrAC samples
can be used as a model to establish the role for
pathogenic KRAS mutations on UrAC pathophysi-
ology and drug sensitivity.
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Additional file 1: Figure S1. Microscopic imaging of 2D and 3D
urachal cancer cell cultures. Example transmitted light microscopy images
of the phenotypes for the cytotoxic drugs at 1250 nM concentration
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Additional file 2: Figure S2. Comparison of the drug primary urachal
cancer cell culture to patient derived bladder cancer cell cultures. A)
Heatmap visualization of the dose response of the urachal cancer cells
MISB18 with four cell cultures established from patients samples of
different bladder cancer types. GR values of < 0 shown in blue. B) GR
metrics describing the sensitivity of the cells to three drugs; afatinib,
AZD2014 and trametinib displaying strongest selective cytotoxic effects
on the urachal cancer cells in comparison to the bladder cancer cell
cultures (data from image-based screening assays). Data available at Men-
deley Data; DOI: https://doi.org/10.17632/kc7wmn3rcs.2.
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